Mid-term beta-blocker treatment after low risk acute coronary syndrome

Abstract

Get full access to this article

View all access options for this article.

References

Rydén

Ariniego

Arnman

et al.

A double-blind trial of metoprolol in acute myocardial infarction. Effects on ventricular tachyarrhythmias. N Engl J Med 1983; 308: 614–618.

Nuttall

Toescu

Kendall

. Beta blockade after myocardial infarction. Beta blockers have key role in reducing morbidity and mortality after infarction. BMJ 2000; 320: 581–581.

Freemantle

Cleland

Young

et al.

Beta blockade after myocardial infarction: Systematic review and meta regression analysis. BMJ 1999; 318: 1730–1737.

Bangalore

Steg

Deedwania

et al.

REACH Registry Investigators. Beta-blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. JAMA 2012; 308: 1340–1349.

Raposeiras-Roubín

Abu-Assi

Redondo-Diéguez

et al.

Prognostic benefit of beta-blockers after acute coronary syndrome with preserved systolic function. Still relevant today?

Rev Esp Cardiol (Engl Ed) 2015; 68: 585–591.

Dondo

Hall

West

et al.

B-blockers and mortality after acute myocardial infarction in patients without heart failure or ventricular dysfunction. J Am Coll Cardiol 2017; 69: 2710–2720.

Zhang

Yuan

Zhang

et al.

Efficacy of long-term β-blocker therapy for secondary prevention of long-term outcomes after coronary artery bypass grafting surgery. Circulation 2015; 131: 2194–2201.

Haffner

Lehto

Rönnemaa

et al.

Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229–234.

Kraal

Sartor

Papini

et al.

Energy expenditure estimation in beta-blocker-medicated cardiac patients by combining heart rate and body movement data. Eur J Prev Cardiol 2016; 23: 1734–1742.

10.

Melloni

Alexander

et al.

Predictors of early discontinuation of evidence-based medicine after acute coronary syndrome. Am J Cardiol 2009; 104: 175–181.